Impact of <i>EGFR</i> genotype on the efficacy of osimertinib in <i>EGFR</i> tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study.

OPTIMAL and ENSURE, phase III studies that evaluated erlotinib compared with platinum doublets, showed a trend toward improved PFS in patients with exon 19 deletions compared with that in patients with L858R point mutations. 24 , 25 Another prospective study of 36 patients treated with either gefitinib or erlotinib observed improved OS among patients with exon 19 deletions as compared with that among patien

also in 53,322 other papers